Multiple Preclinical Programs

About Generate Biomedicines

Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.

About Perspective Therapeutics

Perspective Therapeutics is on a mission to transform cancer treatment with its innovative, image-guided targeted alpha-particle therapy platform. Formed in February 2023 from the merger of Viewpoint Molecular Targeting and Isoray, the company leverages proprietary Pb-212-based radiotherapies and a matched imaging agent (Pb-203) for a precise theranostic approach. Its clinical pipeline includes programs for neuroendocrine tumors (VMT-α-NET), melanoma (VMT01/02), and fibroblast activation protein (PSV359) positive solid tumors, positioning it at the forefront of the next generation of radiopharmaceuticals.

Therapeutic Areas

Other Not Disclosed Drugs